Covariate analysis of tusamitamab ravtansine, a DM4 anti‐CEACAM5 antibody‐drug conjugate, based on first‐in‐human study

Tusamitamab ravtansine is an anti‐CEACAM5 antibody‐drug conjugate indicated in patients with solid tumors. Based on a previous developed semimechanistic model describing simultaneously pharmacokinetic (PK) of SAR408701, two of its active metabolites: DM4 and methyl‐DM4 and naked antibody, with integ...

Descripción completa

Detalles Bibliográficos
Autores principales: Pouzin, Clemence, Tod, Michel, Chadjaa, Mustapha, Fagniez, Nathalie, Nguyen, Laurent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8923727/
https://www.ncbi.nlm.nih.gov/pubmed/35191618
http://dx.doi.org/10.1002/psp4.12769

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8923727/
https://www.ncbi.nlm.nih.gov/pubmed/35191618
http://dx.doi.org/10.1002/psp4.12769

Ejemplares similares